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Abstract
Cancer immunotherapies are showing promising clinical results in a variety of malignancies. Monitoring the
immune as well as the tumor response following these therapies has led to significant advancements in the field.
Moreover, the identification and assessment of both predictive and prognostic biomarkers has become a key
component to advancing these therapies. Thus, it is critical to develop systematic approaches to monitor the
immune response and to interpret the data obtained from these assays. In order to address these issues and make
recommendations to the field, the Society for Immunotherapy of Cancer reconvened the Immune Biomarkers Task
Force. As a part of this Task Force, Working Group 3 (WG3) consisting of multidisciplinary experts from industry,
academia, and government focused on the systematic assessment of immune regulation and modulation. In this
review, the tumor microenvironment, microbiome, bone marrow, and adoptively transferred T cells will be used as
examples to discuss the type and timing of sample collection. In addition, potential types of measurements, assays,
and analyses will be discussed for each sample. Specifically, these recommendations will focus on the unique
collection and assay requirements for the analysis of various samples as well as the high-throughput assays to
evaluate potential biomarkers.
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Background
Cancer immunotherapies such as immune checkpoint
blockade, adoptively transferred T cells and natural killer
(NK) cells, as well as antibody-based interventions and
anti-tumor vaccination, are showing promising clinical
results across a variety of malignancies [1]. Monitoring
the immune response as well as tumor responses follow-
ing these therapies has been important to the advance-
ment of this field, and the identification of predictive
biomarkers as well as early markers of response to new
treatments are important goals of ongoing research in
order to broaden the impact of these therapeutics. The
validation of biomarkers predictive of treatment out-
comes is paramount to identifying the patients who are
most likely to benefit from treatment and/or to provide
an early indication of therapy response (a topic
addressed by WG1). At present no definitive biomarkers
have been identified that can be used to predict which
patients are most likely to have a clinical benefit. In mel-
anoma, several preliminary biomarkers have been inves-
tigated in response to ipilimumab (anti-CTLA-4)
treatment, but none have been validated in subsequent
studies [2–5].
Peripheral blood is a readily (and repeatedly) accessible
compartment that can yield valuable prognostic infor-
mation, but the relationship between local immune re-
sponses within the tumor microenvironment (TME) and
the peripheral immune system remains incompletely
understood. Emerging data show that cancer and im-
mune cells may be phenotypically and functionally
different between primary tumors and metastatic tissues
[6, 7]. Thus, it is often essential to monitor additional
tissues to understand the impact of different immuno-
therapies on the host immune response. For example,
tumor draining lymph nodes (TDLN) represent both a
metastatic site as well as a major site of cancer-immune
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interactions [8, 9], the bone marrow is the dominant
site of tumor involvement in several hematologic ma-
lignancies, and the cross-talk between the host and the
commensal microbiome regulates many physiological
functions including inflammation and immunity [10–12].
In addition, for adoptive cell therapies, it is important to
analyze the administered cells as well as their persistence
and trafficking in vivo.
It is critical to develop systematic approaches to moni-
tor immune responses and to interpret the data obtained
as the number of compartments and potential bio-
markers analyzed increases. Biologic samples can now
be analyzed at the cellular, DNA, transcriptional, epigen-
etic, post-transcriptional and protein levels, and the ana-
lysis of multiple compartments at several levels yields
massive quantities of data, which require the use of
novel analytic bioinformatics methods. The purpose of
this review is to describe systematic approaches to moni-
tor immune responses to cancer immunotherapy. Using
blood, the TME, microbiome, bone marrow (BM) and
transferred T cells as examples, the nature and timing of
the samples that should be collected will be discussed as
well as the potential types of measures, assays, and
analyses. In particular, the unique collection and require-
ments for the analysis of blood and tissue and high-
throughput assays suitable for evaluating these measures
will be described.
Monitoring a study
The advent and implementation of high-throughput
technologies has made personalized, targeted tumor im-
munotherapy possible. In the development of cancer im-
munotherapies, the majority of work was done to
identify proteins that are either overexpressed or mu-
tated in patients’ cancer and could serve as the basis for
a vaccine or of an adoptive immunotherapy. In the fu-
ture, an individual patients’ pattern of serum antibody
binding might be also used for the development of per-
sonalized immunotherapy as well as for monitoring im-
mune responses. In addition, combinations of multiple
high-throughput or “omics” technologies might help to
identify these biomarkers. Predictive biomarkers are also
required to link immunity with an increased likelihood
of improved outcome for patients undergoing different
immunotherapies. Often, the clinical efficacy of im-
munotherapies determined by anti-tumor responses has
been associated with Th1 immunity [13].
For the monitoring of immune cell responses and
tumor assessment using immunological markers, periph-
eral blood (peripheral blood mononuclear cells [PBMC]
and serum) should be collected at baseline, early, middle,
and late time points after onset of treatment with a
follow-up after end of treatment again at early, middle,
and late time points. In addition to conventional clinical
lab analysis of lactate dehydrogenase, C-reactive protein
(CRP), absolute lymphocyte count (ALC), immune cell
repertoire (see flow cytometry), the expression of genes
and proteins should be analyzed in serum/plasma for cy-
tokines, chemokines, putative tumor-associated antigens
and antibodies at the end of dosing and beyond [14].
Emerging studies also suggest the collection and analysis
of tissues, bone marrow (particularly in hematologic ma-
lignancies) and microbiome [15–17].
Immunotherapies have become a standard treatment
for some cancer types. The development and optimization
of cancer immunotherapies to increase their efficacy have
become intensive areas of research. Importantly, the iden-
tification of immune-related biomarkers for diagnosis,
prognosis, monitoring of immune responses and identifi-
cation of their mechanism of action, as well as for the se-
lection of patients undergoing cancer immunotherapies
and the prediction of clinical outcomes are also under
intense investigation. The integration of multiple high-
throughput “omics” technologies, including DNA sequen-
cing, genome wide association studies, which allow for the
identification of single nucleotide polymorphisms (SNP),
and gene expression profiling of mRNA for the analysis of
tumor or PBMC have been used to define such bio-
markers. Furthermore, different proteome-based tech-
nologies, such as the serological evaluation of proteins
and antibodies, top-down and bottom-up proteomics,
multiparameter enzyme-linked immunosorbent assay
(ELISA), and Luminex analyses have been employed for
diagnosis, immune monitoring, immune response assays,
and identification of novel therapeutic targets. The “ome”-
based methods currently available have some advantages
and disadvantages, such as sensitivity, reproducibility,
amount of sample required for analysis, and that they
strongly depend on the data analysis performed.
Materials to be evaluated
An important issue for the development of high-
throughput technologies related to cancer immuno-
therapies is the tissue source, with preference for easily
accessible material, such as body fluids (blood and
urine) rather than serial tumor biopsies, which are pos-
sible for cutaneous melanoma and hematologic malig-
nancies, and more challenging for other tumor types
where core biopsies (if anything) are more common. In
this context, the capacity of the technology, the repro-
ducibility of results, the assay stability and the ability to
validate the results are essential considerations.
Sample generation, isolation, and processing are im-
portant issues, since significant differences have been
observed between different methods and consumables
used for the purification of serum, plasma, and immune
cells obtained from peripheral blood and from tumor tis-
sues [18–20]. In addition, the sample holding times
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before processing (1 – 48 h.), the blood collection
method, and immunoglobulin G (IgG) purification from
these samples could affect analysis, leading to reproduci-
bility problems [21].
Serum and plasma
Serum and plasma samples prepared from peripheral
blood are easily obtainable from patients and are often
collected as a part of clinical studies and stored in bio-
banks. In particular, serum or plasma is collected for the
evaluation of cytokines, chemokines, and growth factors,
as well as other soluble molecules, including antibodies,
matrix metalloproteinases (MMP), and adhesion mole-
cules [22, 23]. In addition, the newly appreciated role of
exosomes and extracellular vesicles (EV) as cancer bio-
markers [24] and in immune surveillance [25], begs for
the development of sample collection methods compat-
ible with multiple downstream analyses, including that
of exosomes/microvesicles. The considerations linked to
the choice of the source (whole blood versus plasma or
serum), and the method of purification have been dis-
cussed in a position paper from the International Society
of Extracellular Vesicles [26], which concluded that
plasma is the most physiological relevant milieu to study
blood EV. If such studies are envisioned, then plasma
should be collected.
Serum samples can be collected using silica-coated
serum separating tubes. Serum can then be incubated at
a dilution of 1:50 in 0.5% casein-PBS (phosphate buff-
ered saline) blocking buffer to suppress non-specific
binding of sera proteins. For Luminex and ELISA,
plasma samples can be collected in tubes containing one
of three distinct anti-coagulants: (i) sodium heparin, (ii)
sodium citrate dextrose and (iii) ethylenediaminetetra-
acetic acid (EDTA) [27].
To determine the serum peptidome profile, three dif-
ferent protocols can be used for mass spectrometric ana-
lyses of serum and plasma proteins. For the first, crude
plasma samples can be directly subjected to tryptic
cleavage. Otherwise, buffer components can be removed
from the samples and samples can be concentrated
using macro spin plates. For the third protocol, the
process of depletion can be carried out using a proteo-
prep immunoaffinity albumin and IgG depletion kit,
followed by trypsinization and peptide extraction on
macro spin centrifuge plates. The protein digestion can
be performed using trypsin at 37 °C for three hours with
stirring. The trypsinization is then terminated by adding
trichloroacetic acid, the pH adjusted, the trypsinized
plasma is dried, resolved in liquid chromatography solu-
tion, spiked with isotypically labeled peptide standard
and then used for mass spectrometric analysis [28]. Sam-
ple collection and preparation are critical steps to obtain
useful information in clinical proteomics analyses. To
circumvent undesirable degradation of proteins and pep-
tides, serum samples should be collected under specific
standard operating procedures (SOP). However, the
current protocols and guidelines for human bodily fluid
collection and storage prior to proteomic analysis, in
particular regarding blood plasma and serum, still need
to be optimized. The influence of pre-analytical factors
on the serum peptidome profile is significant, especially
the type of blood collection tube, variations in clotting
time and temperature, storage conditions, and the num-
ber of freeze and thaw cycles [29–32].
Briefly, all venous blood specimens should be collected
with vacuum blood collection tubes. After standing up-
right at room temperature for 60 min, the serum frac-
tion is separated by centrifugation at 1500 x g for
15 min (4 °C) and immediately stored at -80 °C. Only
one freeze and thaw procedure can be permitted for any
serum sample used for mass spectrometric analysis (this
is also critical for other assessments by approaches, such
as Luminex because analytes are differentially sensitive
to freeze/thaw cycles). The selection of the preservatives
and additives used in the collection of blood is import-
ant in determining future applicability of the samples.
For example, the collection of whole blood in tubes con-
taining any type of anti-coagulant may induce cytokine
production in vitro and thus results in artificial measures.
Some coagulants are recommended or even required for
particular analytical purposes, while others might be
contraindicated [33].
The samples should be collected prior to treatment
(baseline) and at various time points (e.g., early, middle,
and late depending on the treatment interval) during
therapy as well as after therapy (early, middle, and late
time points). The samples should be aliquoted prior to
freezing.
Leukocytes
Complex immunoregulatory circuits, including the low
frequency and activity of effector cells and high frequency
of suppressive cells, have the potential to dampen the effi-
cacy of immune interventions, thus cellular immune as-
sessments should be considered an essential component
of monitoring efforts in cancer immunotherapy clinical
trials. Immune monitoring of peripheral blood and tumor
immune cell infiltration offers insights into the mecha-
nism(s) of action of immunotherapeutic strategies and
may be prognostic of outcome. However, the selection of
the methods and components analyzed during cellular
monitoring of clinical trials clearly depends on the individ-
ual therapeutic modality and disease being investigated.
For these analyses, PBMC obtained from fresh anticoa-
gulated whole blood are isolated by gradient centrifuga-
tion using ficoll or Histopaque®. Platelets are removed
and any remaining contaminating red cells can be
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eliminated with ammonium chloride potassium (ACK)
lysing buffer prior to the use of the cells for downstream
analyses, e.g., flow cytometry, transcriptomics, and pro-
teomics. It is noteworthy that hemolysis during sample
preparation could significantly affect the biomarker con-
tent of e.g. cytokines, microRNA (miRNA) [34].
Leukocyte counts
Recently, studies have indicated that early changes in
immunological markers may be associated with im-
proved survival. To date, many of these signals have
come from single analyte measures tested in some trials
and not others, or from common clinical laboratory
tests. Increases in ALC and eosinophil count after treat-
ment with ipilimumab 3 mg/kg both correlated with im-
proved survival [35]. Additionally, among 27 patients
treated with ipilimumab 10 mg/kg, changes in the num-
ber of circulating T cells that expressed ICOS during the
early treatment stages and a low ratio between absolute
neutrophil count and ALC were also associated with bet-
ter survival [36]. This is consistent with other analyses
of patients treated in the expanded access program,
where a high ALC after two doses of ipilimumab or at
6 weeks was significantly associated with survival [4, 37].
The association of changes in ALC with survival was
also recently assessed among approximately 2000 pa-
tients who had received ipilimumab (at various doses as
a monotherapy or in combination with chemotherapy)
as part of their treatment regimen. Consistent with its
proposed mechanism of action, treatment with ipilimu-
mab resulted in an increase in mean ALC. However,
while a positive association was observed between the
rate of increase in ALC and survival, absolute changes in
ALC were not found to be specifically predictive of im-
proved survival [38]. By contrast, Simeone and co-authors
showed that an increase in ALC between baseline and
week 12 was significantly associated with disease control
and survival in patients treated with intravenous ipilimu-
mab 3 mg/kg every 3 weeks for a total of four doses [14].
Since ALC is a single analyte, further investigations into
the utility of ALC as a prognostic biomarker of response
to new drug activity are warranted, and it is suggested to
combine ALC with other candidate markers.
T cells
It is now established that the infiltration of tumors by T
cells can affect tumor growth, invasion, and patient out-
come. Several studies have highlighted the correlation
between ALC and clinical outcome both in patients with
hematological malignancies and in those with solid tumors
[39–41]. A conspicuous (“brisk”) lymphocyte infiltrate cor-
relates strongly with a positive outcome in melanoma and
in colorectal cancers (CRC). A follow-up study of 2845
patients with invasive primary melanoma has shown that
death as a result of melanoma was 30% less with non-brisk
tumor infiltrating lymphocyte (TIL) grade and 50% less
with brisk TIL grade when compared with the absence of
TIL independently of tumor characteristics currently used
to define the melanoma stage [42]. In general, TIL express
a CD3+CD8+CD45RO+ phenotype [43].
Numbers of CD8+ T cells correlate with improved
outcome in various tumor types, including lung cancer
and CRC [44, 45]. In contrast, tumor-infiltrating CD4+
T cell numbers may portend both favorable and unfavor-
able implications for patients’ survival. Regulatory T cells
(Treg) express CD4 and reportedly constitute 5-15% of
infiltrating CD4+ T cells in tumor samples [46]. The ra-
tio of CD8+ T cells to Treg in TIL has been correlated
with aggressive growth and poor response to chemother-
apy in several tumor types, including urothelial carcin-
oma of the bladder [47], serous ovarian cancer [46, 48],
squamous cell carcinoma [49], pancreatic cancer [50],
breast cancer [47], and colorectal cancer [51, 52], and
can separate cancer survivors from non-survivors [53].
In some tumor types, Treg accumulation correlates
with a better prognosis. For example, in a large series
of 967 stage II and stage III CRC, a high density of
FoxP3-expressing intra-tumoral Treg was associated
with improved survival and showed stronger prognostic
significance than CD8+ T and CD45RO+ T cells [54]. A
consensus on the marker set and gating strategy used
for enumerating Treg in clinical samples has been re-
cently established [55], with CD3, CD4, CD25, CD127,
and FoxP3 markers as the minimally required markers
to accurately identify human Treg. Furthermore, stain-
ing for Ki67 and CD45RA might provide useful infor-
mation on the activation status of this cell population.
The marker set was validated using PBMC from cancer
patients as well as cells from TDLN and fresh tumor
samples. A phenotyping panel that is not limited by the
constraints of intracellular staining has been proposed
by Roederer [56], and it considers Treg markers of acti-
vation and suppression. Other activation markers, such
as CD39, CTLA-4, LAP, GARP, PD-1, and PD-L1,
should be included in the monitoring of Treg for can-
cer patients as surrogate markers for Treg function and
potentially eliminating the need for Treg isolation and
in vitro suppression assays [57].
During the expansion phase that follows administration
of blinatumomab, a bispecific CD3 and CD19 antibody,
to patients with B cell precursor acute lymphoblastic
leukemia, bone marrow-infiltrating T cells express a
skewed T cell receptor (TCR) repertoire compared with
peripheral blood T cells suggesting that clonal expansion
occurred within the TME and might affect clinical out-
come [58]. Massive parallel sequencing can be used to
characterize the complete immune repertoire of patients.
ImmunoSEQ (Adaptive Biotechnologies, Seattle, WA)
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offers a proprietary suite of high-throughput immune pro-
filing assays and powerful online software. Multiplex PCR
primers target all possible combinations of the noncontig-
uous (Vβ), diversity (Dβ), and joining (Jβ) gene segments
of the β chain locus. The result of such an assay is millions
of sequences per sample – and a quantitative description
of the immune cell populations [59].
Myeloid cells
Tumor-associated macrophages (TAM) comprise up to
50% of malignant tumors. Due to their plasticity, it has
been challenging to measure and classify these cells.
TAM can be reprogrammed to type 2 macrophages
(M2) by microenvironmental factors, as a result of alter-
native activation by Th2-biased cytokines, such as IL-10
[60]. M2 macrophages can be identified based on their
expression of CD163 (scavenger receptor) and CD206
(mannose receptor) coupled with traditional monocyte
markers such as CD14, HLA-DR, and CD11b. Although
tumor infiltration with TAM has been demonstrated to
correlate with poor clinical outcome, recent studies have
suggested that high TAM densities could also be predict-
ive of better patient survival as shown in prostate cancer
[61]. Thus there is an urgent need to harmonize the
phenotypic studies to accurately discriminate M1 from
M2 macrophages and to correlate the density of macro-
phage populations with clinical outcome following
immunotherapy [62].
Myeloid-derived suppressor cells (MDSC) consist of
immature myeloid progenitor cells with the ability to
suppress proliferation and effector functions of T cells
[62, 63]. MDSC are expanded in patients with a variety of tu-
mors. In contrast to murine MDSC, the markers used for
identification of human MDSC subpopulations are still
under discussion. In human PBMC, monocytic and granulo-
cytic MDSC exhibit a CD11b+HLA-DRneg/lowCD14+CD15-
and CD11b+CD14-CD15+ or CD11b+CD14-CD66b+
phenotype, respectively [64]. While monocytic MDSC ex-
press the myeloid marker CD33, granulocytic MDSC display
CD33dim staining. Furthermore, HLA-DR-CD33+ cells con-
tain mixed groups of MDSC comprising more immature
progenitors. It has been proposed that HLA-DR-CD33+
cells be defined as ‘early-stage’ MDSC [64]. A study analyz-
ing the efficacy of multi-peptide vaccination in patients with
renal cell carcinoma (RCC) showed that two out of six
phenotypically-defined MDSC populations were of prognos-
tic value for overall patients’ survival [65].
Monocytes and Antibody-Dependent Cellular Cytotoxicity
Intriguingly, in a study of 29 patients with advanced cuta-
neous melanoma treated with ipilimumab it was shown
that ipilimumab can engage ex vivo CD16-expressing,
non-classical monocytes (CD14+CD16++), resulting in
antibody-dependent cellular cytotoxicity-mediated lysis of
Treg [66]. Patients responding to ipilimumab display sig-
nificantly higher frequencies of non-classical monocytes at
baseline compared with non-responder patients.
The diagnostic potential of intermediate CD14++CD16+
monocytes has also been shown in patients with CRC [67].
Intermediate monocytes were significantly elevated in these
patients, with the highest frequencies detected in those with
localized disease. The frequency of CD14+CD16+ mono-
cytes was negatively associated with tumor size and patho-
logical stage in patients with breast cancer [68]. The
expansion of intermediate monocytes could be driven by
monocyte chemoattractant protein-1 (MCP-1), which may
be inhibited by the addition of neutralizing antibodies
against MCP-1 to the monocyte cultures [68]. Finally,
vaccination of patients with stage IV melanoma using
Melan-A/MART-1:26-35(27 L) and gp100:209-217(210 M)
peptides might augment the frequency of CD14+CD16+
monocytes as well as their expression of CD40/CD86 co-
stimulatory molecules and antigen-presenting function
[69]. Increases in both intra-tumoral and circulating
CD14+HLA-DRlow/neg monocytes have been correlated
with poor prognosis in RCC patients [70].
Tissue analysis
While less invasive for patients in comparison to tissue
biopsies, the degree to which peripheral immune moni-
toring is appropriate and useful in a given therapeutic
context depends upon the treatment modality in ques-
tion. Measures of peripheral antigen-specific T cells elic-
ited by vaccines or persisting in the circulation following
the administration of T cell based therapies have shown
correlations with clinical outcome in some studies [71, 72],
but not in others [73–75]. In the context of immune check-
point blockade, anti-CTLA-4-directed agents have been
suggested to expand the breadth of antitumor immunity
through peripheral T cell priming [76], whereas PD-1/PD-
L1-directed therapy is thought to predominantly act at the
level of the TME in tumors with a pre-existing T cell infil-
trate [77]. Therefore, the ability to detect pharmacodynamic
changes in peripheral blood lymphocyte populations or sol-
uble serum factors that are relevant for treatment outcome
may differ between these agents and across various im-
munotherapies in general. More broadly, a comprehen-
sive and integrated biosampling approach of tissue
and peripheral blood in the clinical setting as well as
in preclinical models may allow the identification of
less invasive biomarkers that reflect clinically mean-
ingful aspects of the immune TME, which will im-
prove the triage and management of patients in the
era of cancer immunotherapy. Overall, new tissue
analysis tools, rigorous validation, and standardization
of methods will help us understand better the dy-
namic nature of immune-tumor interaction [78].
Stroncek et al. Journal for ImmunoTherapy of Cancer  (2017) 5:21 Page 5 of 23
Tissue collection and variability
Significant hurdles exist to the use of archival, fresh
tumor biopsies, and TDLN samples for correlative stud-
ies. In particular, sample quantity, variability in sample
handling and processing, and tissue heterogeneity may
all impact the pre-analytical variability of tumor-based
immune assays. The volume of tumor tissue routinely
obtained in diagnostic biopsies is often limiting for the
purposes of high-dimensionality immune monitoring
and necessitates a rigorous assessment of assay require-
ments and prioritization of sample workflow. Moreover,
the quality of such routinely obtained tissues may be
highly variable. Core or needle biopsies taken from dif-
ferent parts of a tumor mass may manifest significant
differences in tumor, stromal, and immune cell compos-
ition. For surgical or excisional samples, warm and cold
ischemia time is a critical parameter impacting the suit-
ability of the tissue for use in complex immunoassays.
Similar considerations apply for the handling of core or
needle biopsy samples. Procedures for tissue collection,
formalin fixation, and paraffin embedding remain non-
standardized across institutions, while standardized pro-
tocols for other forms of tissue disposition (freezing,
preservation in a nucleic acid stabilization medium such
as RNAlater™, direct fresh tissue handling) are often not
in place.
Despite these limitations, significant insights into tumor
immunobiology have been made using archival formalin-
fixed, paraffin-embedded (FFPE) samples. However, work-
ing with such samples requires rigorous characterization
of pre-analytical variability as it impacts the intended set
of assays, followed by hypothesis testing in an appropri-
ately sized dataset that takes into account the anticipated
pre-analytical variability. Analytical variability may further
compound data quality and interpretation, particularly as
it impacts the ability to make comparisons across different
studies (this is addressed in greater detail by Working
Group 1). For example, differences in sensitivity and speci-
ficity of detection antibodies for immunohistochemistry
(IHC) or flow cytometry, the qualitative and quantitative
scoring algorithms (e.g., analysis of whole tissue sections
vs fields of view in IHC), and different method-based reac-
tion principles (e.g., NanoString based gene expression
profiling [79] and full RNAseq), represent only some pa-
rameters that will complicate direct data comparison.
As patients are exposed to an ever-increasing repertoire
of immunotherapies and other anticancer agents, archival
tissue, mostly originating from primary diagnostic biop-
sies, is less likely to be representative of the immune
microenvironment at the time of disease progression or
relapse. In these cases, fresh tumor biopsies are warranted
to characterize tumor immune status at relapse/progres-
sion. More generally, because of the factors cited above
that impact the pre-analytical variability of archival tissue,
dedicated research biopsies taken in the context of de-
tailed SOP for sample acquisition, annotation, handling,
and disposition are preferable to archival tumor specimens
whenever feasible, acceptable for study design, and ethic-
ally appropriate. Dedicated research personnel should be
utilized and given responsibility for tissue acquisition and
transport, physician training, and other aspects of sample
acquisition and handling. Moreover, surgeons, interven-
tional radiologists, and others obtaining samples should
be properly trained and tightly integrated into the research
team. Inclusion of patients as well as clinical personnel in
the scientific discussion, when feasible, will increase pa-
tient willingness to donate tissue specimens and ultimately
result in better sample quality. Further, proper annotation
of research samples is critical to document the anatomic
site (preferably including sub-localization within a given
lesion), as well as parameters related to tissue collection
and handling, such as time from biopsy/excision to fix-
ation (warm and cold ischemia time), and freezing or
other storage/processing steps. Where feasible, samples
should be annotated with data related to the location of
the lesion on radiographic imaging to allow for appropri-
ate data interpretation in the respective context and the
longitudinal resampling of the same anatomic site.
Multi-institutional studies
Special considerations are necessary when performing
tumor immune monitoring in the context of multi-insti-
tutional studies. Quality control measures and analytical
approaches should be put in place to both minimize and
quantify site-dependent variability. This can include cen-
tralized specimen shipping kit preparation, overnight spe-
cimen shipment in temperature controlled containers,
and processing upon arrival. For example, standardized
approaches to sample processing, fixation and embedding
(or alternate tissue preparation approaches appropriate for
a given protocol), as well as sample storage and shipping
should be used. It is desirable to centralize as many analyt-
ical steps as possible, including tissue sectioning and prep-
aration (e.g., nucleic acid extraction) and analytical assay
work. Samples received from multiple institutions should
be analyzed in batches, and batched (or real-time) analysis
should be used to support the early detection of pre-
analytical or analytical quality control issues to ensure that
these sources of variation are minimized. Any potentially
problematic samples should be annotated accordingly to
flag them.
Other sources for variability
Pre-analytical variability is influenced not only by tech-
nical factors, but also by biological heterogeneity. Where
such heterogeneity cannot be fully controlled, it must be
well characterized in order to guide the proper design of
hypothesis-driven translational research studies [80].
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Intra-tumoral heterogeneity of tumor cell clonotypes has
been clearly documented through the observation of dis-
tinct somatic mutation profiles at different regions
within a single lesion [81, 82]. Clonotypic heterogeneity
between primary and metastatic lesions and from one
metastasis to the next has also been well documented
and can directly translate to the heterogeneity of clinical
response between lesions within a single patient, which
impacts overall disease outcome and treatment oppor-
tunities [6, 7]. Likewise, the immune TME may exhibit
inter- and intra-lesional heterogeneity. For example, PD-
L1 expression has been observed to be discordant between
tumor sites in some cases [83]. Preliminary data also show
significant intra-patient, inter-lesional diversity in TCR
clonality and immune gene expression.
Experimentally, such biological heterogeneity can be
controlled for in several ways. At the most basic level,
routine morphologic characterization by hematoxylin
and eosin (H&E) or cytokeratin staining is critical for
confirming the histology of each sample, and SOP that
utilize these data to determine sample adequacy and uni-
formity should be utilized. Where possible two or more
cores should be evaluated; multiple cores should be
combined for technical approaches that do not preserve
geospatial data (e.g., gene expression profiling, whole ex-
ome sequencing, TCR deep sequencing, bulk proteomics),
in order to compensate for intra-tumor heterogeneity.
Where more uniform sampling of specific cell populations
is desired, laser capture microdissection can be utilized for
cell isolation.
Early insights into the TME and immunotherapy
Regardless of these analytical challenges, significant in-
sights have been made into the biology of the tumor im-
mune microenvironment by direct interrogation of tumor
tissue. In particular, methodologies for interrogating the
tumor-immune interface have demonstrated both prog-
nostic and predictive values in the setting of checkpoint
blockade immunotherapy. As discussed elsewhere, both
detailed measures of tumor immune infiltration (the
immune contexture) and more streamlined biomarkers
representing the same phenomenon (the immunoscore)
have shown prognostic value in CRC that may exceed that
of traditional TNM staging [44, 84]. These data show that
spatial distribution of immune cell infiltrates within the
TME will be as important as quantitative assessment to-
ward understanding the underlying biology.
Despite the documented geospatial and temporal het-
erogeneity of PD-L1 expression, PD-L1 on both tumor
cells and immune-infiltrating cells has been shown to be
a sensitive and specific biomarker of response to PD-1/
PD-L1 directed therapies in tumor types such as non-
small cell lung cancer (NSCLC) and urothelial carcin-
oma [85, 86]. Such insights have been made using
archival FFPE samples, often of variable age relative to
time of study enrollment. More recently, additional bio-
markers have demonstrated predictive value in the setting
of CTLA-4 or PD-1-directed immunotherapy, although
the performance characteristics of these biomarkers have
not yet been fully elucidated. These include measures of
non-synonymous mutational load and predicted neoepi-
topes [87–90], TCR clonal diversity [91], apposition of
PD-1 and PD-L1 on adjacent T cells and tumor/stromal
cells [91], direct correlation of mutational tumor load and
TIL infiltration [92], and expression of cytotoxicity or
IFN-γ-associated genes characteristic of a T cell inflamed
microenvironment [89, 93].
These data indicate that properly controlled tissue
acquisition and analysis, as well as the use of comple-
mentary and reinforcing technologies (e.g., orthogonal
characterization of biomarkers by multiplex IHC [94] and
gene expression profiling), could overcome issues related
to pre-analytical and analytical variability, allowing for re-
producible assessment of clinically meaningful biomarkers
in the TME. Furthermore, additional development and in-
vestment in such technologies will allow the use of more
effective combinations of tissue analysis tools with limited
material that is available in a clinical setting.
Bone marrow
Evaluation of anti-tumor immunity in hematologic ma-
lignancies should include an evaluation of the bone
marrow [17]. Indeed, several studies have shown that
properties of T cells or other immune cells within the
bone marrow of patients with hematologic malignan-
cies may differ considerably from those in the circula-
tion [95–97]. Evaluation of the bone marrow is typically
performed with a bone marrow aspirate as well as a
bone marrow (trephine) biopsy. Below, we describe
some of the key considerations when analyzing immune
responses in the bone marrow.
Collection and adequacy of the specimen
Technical considerations for ensuring the collection of
adequate specimen are perhaps the most important
element for quality control. It is therefore essential that
the aspirate be analyzed at the bedside for adequacy of
the specimen per the International Council for
Standardization in Hematology (ICSH) guidelines [98].
Large volume aspirates from a single site may simply
lead to dilution from peripheral blood and should be
avoided. Use of needle redirects to access different re-
gions of the bone through a single skin puncture may
be useful but still carry the risk of aspiration from a
hemorrhagic site. When possible, we recommend
obtaining a paired blood sample so that the phenotypic
and functional aspects of blood versus marrow mono-
nuclear cells may be directly compared. For example, in
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contrast to the peripheral blood, T cells in the human
marrow are mostly memory T cells and are enriched
for CD8+ T cells [99]. Bone marrow samples collected
in sodium heparin are sufficient for most immune
monitoring assays wherein analysis by flow cytometry
or mass cytometry is the focus [99]. However, EDTA
may be the preferred anticoagulant in some instances,
particularly when concurrent PCR-based molecular
studies are desired. When quantitative changes in im-
mune cell populations during immunotherapy are con-
sidered important, it is recommended that the sample
dedicated for immune monitoring should be the first
sample from the collection site [100]. In contrast to the
clinical diagnostic samples which typically get priori-
tized, this often requires a needle redirect. In addition
to the aspirate, collection and evaluation of the biopsy
specimen is essential to gain insights into the location
of immune cells and cell-cell interactions. ICSH guide-
lines recommend that at least 2 cm cores should be ob-
tained. In settings wherein the amount of aspirate is
inadequate, we suggest routinely obtaining touch prep-
arations of the marrow biopsies. Finally, we strongly
recommend that immune monitoring protocols for the
marrow (at least those intended towards discovery of
new targets) routinely include the preparation of “par-
ticle clots” using published guidelines [98, 101]. This is
because processing of marrow biopsies typically in-
volves decalcification protocols, which cause nucleic
acid or protein damage and impact staining for several
antigens. Clot sections do not require decalcification.
Another approach is to consider snap-freezing a small
(e.g., 0.5 cm) portion of the core, which can subse-
quently be utilized for analysis of gene expression and
downstream deconvolution of data [102].
Specimen transport and initial processing
As with peripheral blood, marrow aspirates can be safely
transported overnight at room temperature to reference
laboratories, and such transport protocols have been
successfully utilized in large multicenter studies involv-
ing correlative studies on bone marrow specimens
[103]. Transport on ice or at lower temperatures leads
to loss of mononuclear cell yield. Marrow aspirates also
seem to have a greater tendency to clot than blood
samples, and it is therefore essential to ensure ad-
equacy of anticoagulant in the tube. Trephine core bi-
opsies are typically added to the fixative at bedside and
may be fixed using several different methods. A stand-
ard fixative is neutral buffered formalin. Fixation times
vary between 1 and 24 h, but are typically 4–6 h. We
strongly recommend using a pre-specified fixation time
for all specimens in a clinical trial. Fixation longer than
24 h may negatively impact antigen retrieval and should
be avoided.
Further processing and downstream applications
In contrast to other tissues, isolation of mononuclear
cells from the bone marrow does not require enzymatic
digestion steps. However, for samples with particulate
appearance, we recommend initial dilution of the aspirate
in sample buffer and use of a 0.1 micron filter to remove
particulate/bone fragment debris. Ficoll density gradient
centrifugation remains the most common approach
for the isolation of mononuclear cells from the bone
marrow. Mononuclear cells isolated from the marrow
aspirate have been successfully utilized for a range of
downstream immune monitoring assays including flow
cytometry based assays, ELISPOT, MHC tetramers,
mass cytometry, TCR sequencing as well as genome
wide analyses of sorted cells [99, 100, 104, 105].
Trephine biopsies also require decalcification, which
can be achieved by several methods. Decalcification
with EDTA results in better preservation of nucleic
acids but is slower than other acid reagents [98]. The
combination of neutral buffered saline fixation followed
by EDTA decalcification is the current format preferred
by most investigators, as it provides adequate morph-
ology, preserves nucleic acids for molecular studies,
and antigens for IHC.
Microbiome
The analysis of the microbiome is not yet routinely
part of the evaluation of immunity in cancer patients
and in immunotherapy trials; however, emerging evi-
dence of the important role of the microbiome in
modulating anti-cancer immunity and the effectiveness
of different types of cancer therapy suggests that this
analysis could provide important information regarding
the immune status of the patients and their ability to
respond to therapy. Biomarkers could be identified and
the microbiome could possibly be targeted to improve
therapeutic response.
The microbiome modulates cancer initiation, progression
and response to therapy
Similar to all mammalian organisms, the epithelial barrier
surfaces in the human body are colonized by commensal
microorganisms (the microbiome) with the largest micro-
bial mass present in the lower intestine [106]. Thus, we
are meta-organisms, or symbionts, in which our host cells
and the microbial cells cohabit and interact with each
other [107, 108]. By regulating human physiology and, in
particular, inflammation and immunity, the presence and
composition of the microbiome can affect cancer initi-
ation, progression, and response to therapy [109–111].
Viruses and bacterial species have been implicated in
oncogenesis [112]. Infection with one bacterial species,
Helicobacter pylori, has been clearly associated with
stomach cancer, and it is recognized as a class 1 human
Stroncek et al. Journal for ImmunoTherapy of Cancer  (2017) 5:21 Page 8 of 23
carcinogen [113]. However, several bacterial species have
been described that are likely to be involved in the initi-
ation and progression of other cancers such as CRC and
gallbladder cancer [109, 114]. In addition, the compos-
ition of the microbiome at the epithelial barriers may
affect the progression of tumors in sterile tissues not dir-
ectly colonized by the microbiome [115]. The micro-
biome composition in cancer patients may be altered
due to the presence of the tumor and to a larger extent
due to the effect of therapeutic treatments. Use of antibi-
otics, radiation, and chemotherapy treatments induce
persistent changes in the composition of the micro-
biome, often associated with a reduction in the number
of bacterial species present. Following allogeneic bone
marrow transplantation, the diversity of the intestinal
microbiome at engraftment is an independent predictor
of mortality, with higher diversity predicting a more fa-
vorable outcome [116]. Recently, experimental evidence
as well as initial data in patients have shown that the
efficacy of anti-cancer therapy, including adoptive T cell
transfer after total body irradiation, immunostimulating
oligonucleotides, chemotherapy with cyclophosphamide
and platinum compounds as well as immune check-
point inhibitors, requires the presence of the intestinal
microbiome and is affected by the microbial compos-
ition [15, 16, 117–119]. The anti-cancer mechanisms of
these therapies rely on the ability of the gut micro-
biome to educate infiltrating immune cells that produce
inflammatory mediators required for the direct antitu-
mor effects of therapy and promote the generation of
an anti-tumor adaptive immune response [120]. Several
microbial genera or species that promote or antagonize
the effect of different types of cancer therapy or the
anti-tumor host immune response have been identified.
The study of the composition of the microbial com-
munities in the stool or at other anatomical sites of
cancer patients before and after therapy could provide
information about the immune status of the patients
and contribute to the identification of future bio-
markers for prediction of disease progression and re-
sponse to therapy. The presently available information
has been largely obtained in experimental animals, so it
will be necessary to collect a wide range of information
from clinical studies before being able to evaluate the
prognostic significance of the findings and the identifi-
cation of biomarkers. However, this type of analysis has
great potential to provide clinically significant informa-
tion. In addition, there has been important progress in
the development of new methodologies to modify the
composition of the microbiome, suggesting the possi-
bility that the microbiome could be targeted to slow
tumor progression, prevent cancer co-morbidities, en-
hance cancer therapy efficacy, and to attenuate treat-
ment toxicity.
Development of microbiome studies
Until recently, the study of microbes in human samples
relied on labor-intensive microbiology techniques for
growing and collecting individual isolates, the data from
which were influenced by cultivation conditions. These
methods did not allow for complete profiling of the mi-
crobial communities present in the samples; however,
the advent of next generation DNA sequencing methods
has advanced microbial investigations. The most com-
mon approach for microbiome studies is the amplifica-
tion and sequencing of variable regions in the bacterial
genes encoding 16S ribosomal RNA to determine the
taxonomic composition of the microbiome by compar-
ing them to existing databases. Thus, 16S rRNA gene se-
quencing permits a more comprehensive assessment of
the bacterial communities present in a clinical sample.
When incorporating microbiome approaches to cancer
studies, each element of a microbiome study is critically
important [121].
Collection of specimens
The collection of specimens and metadata significantly
influences the ability to derive clinically relevant down-
stream analyses. Many factors are important to consider,
including determining the body site(s) of interest, e.g.,
stool, skin, oral mucosa, vaginal mucosa; selection of
cases and controls; frequency of sampling; and method
of collection. Because sites with little spatial separation
can harbor distinct bacterial communities, consistency
in sample collection is important [122, 123]. Predomin-
ant bacterial taxa and the microbial biomass are body
site-dependent and location identity will determine the
methods for collecting specimens and relevant metadata
[124]. Most oncology studies that have included micro-
biome approaches have focused on stool [15, 118, 119].
While various stool sampling and storage methods have
been studied, feasibility (e.g., accessibility to storage
freezers) and patient participation (e.g., self-collection)
may guide selection of optimal collection methods
[125–127]. Depending on the clinical study, tumor
type, and/or therapeutic intervention, the other com-
monly studied body sites of skin, oral mucosa, and
vaginal mucosa may provide distinct and informative
microbiome data. Identifying appropriate controls for
oncology patients may be challenging; alternatively,
repeat samplings of the same patients can provide in-
ternal controls, particularly if specimens are collected
both prior to and after a clinical intervention.
Sequencing and analysis
Given the potential sources of variation in microbiome
studies, standardization is crucial for study quality and
reproducibility [128]. After collection and processing of
specimens, regions of bacterial 16S ribosomal RNA gene
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are amplified and sequenced. Because newer sequencing
platforms do not sequence the complete 16S rRNA
genes, only some of the variable regions can be selected
and sequenced, which allows effective identification of
the genera present but can reduce the ability to identify
bacteria at the species level. Primer selection is usually
based on the source of the clinical biospecimens, e.g., V4
primers for stool samples and V1-3 primers for skin
samples, to optimize species-level identification of se-
quences [129]. Different platforms can be used for ampli-
con sequencing. At present, the Illumina’s MiSeq is the
most commonly used.
Various pipelines and tools are available to facilitate
analyses of amplicon sequencing data. Most popular are
Quantitative Insights Into Microbial Ecology [130] and
mothur [131]. Alternatively, all genes in all microorgan-
isms in a given sample can be analyzed by shotgun
metagenomic sequencing. Metagenomic analysis allows
identification not only of bacteria, fungi, and viruses
present in a sample but also which genes and gene func-
tions are present in the community. More recently, meta-
transcriptome analysis has been used to sequence the
RNA in a sample and to evaluate which genes are tran-
scribed, and to what extent. Metagenomic and metatran-
scriptomic analyses require a much higher depth of
sequencing (and higher costs) to obtain sufficient coverage
of the different microorganisms, and the bioinformatics




Peptide-MHC microarrays and other multimeric tech-
nologies have been developed as high-throughput tech-
nologies for the evaluation of antigen-specific T cell
responses [133, 134]. Peptide-MHC multimers tagged
with unique DNA barcodes have been recently used for
multi-parallel screening of >1000 T cell specificities in
complex cellular suspensions [135]. Biotinylated DNA bar-
codes and peptide-MHC molecules are attached to a PE-
labelled dextran backbone carrying streptavidin. MHC
multimers-binding T cells can be sorted based on the PE
label. DNA barcodes are amplified and sequenced, and the
relative numbers of DNA barcode reads is used to deter-
mine the composition of antigen-responding T cells in a
single sample. This technology has allowed for the identi-
fication of melanoma-associated T cell specificities in two
melanoma samples directly after enzymatic digest, where
the number of TIL was 18,000 and 48,000, respectively
[135]. T cell populations were detected in the frequency
range of 20-0.01% of CD8+ T cells. Furthermore, specifi-
city profiling was corroborated by assessing functional re-
sponsiveness by intracellular cytokine staining upon virus
and cancer target recognition. The use of DNA barcode-
labelled MHC multimers also enabled the detection of
neoepitope-specific T cell populations in cancer patients
directly from peripheral blood, with important implica-
tions for immune monitoring studies.
Cytometry by Time-Of-Flight (CyTOF)
Mass cytometry is a fusion of two experimental plat-
forms, i.e., flow cytometry and elemental mass spec-
trometry, and was initially developed to increase the
number of cellular parameters that could be quantified
simultaneously [136, 137]. Rather than coupling probes
(often antibodies) to fluorophores, mass cytometry ex-
periments utilize probes chelated to unique stable,
heavy-metal isotopes, such as the lanthanide series metal
ions, which bind targets of interest on and/or within the
cell, enabling the attached metal ions to serve as re-
porters for the expression level of up to 40 targets [136].
Efforts are currently ongoing to harmonize individual
mass cytometers’ performance to a common standard of
signal intensities and detection limits [138]. Mass cytom-
etry has been recently used to dissect the human muco-
sal immune system in health and disease, allowing the
identification of 142 immune subsets with tissue and
disease specificity [139]. This technology is expected to
impact immune monitoring strategies and to accelerate
the development of individualized therapeutics.
High-throughput proteome-based technologies
Antibodies detected in the serum of tumor patients can
help to identify tumor-associated antigens (TAA) as po-
tential markers for early diagnosis of cancer, for progno-
sis, for prediction of therapy response as well as for
identification of therapeutic targets [140]. To facilitate
autoantibody discovery, several different strategies have
been developed to simultaneously identify multiple anti-
bodies. Technologies currently available for serologic
analyses include SEREX (serological identification of anti-
gens by recombinant expression cloning), phage display,
SERPA (serological proteome analysis)/PROTEOMEX
(proteomics combined with SEREX), different protein
arrays, SomaScan, and MAPPing [141].
SEREX
SEREX has been developed primarily for the determin-
ation of humoral immunity to TAA by using tumor
cDNA libraries in lambda vectors expressed in E. coli,
which are then transferred to nitrocellulose membranes
and incubated with sera from cancer patients and re-
spective control donors. The clones reactive to sera are
identified by sequencing [142].
Using this method >1000 TAA have been identified,
including NY-ESO-1, which was discovered from an
esophageal cancer cDNA library. Next to the use in hu-
man patients and clinical trials, SEREX has been also
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employed in murine transgenic models to predict TAA.
Furthermore, a sera database has been established,
which is for public access and allows the addition of data
from other centers. However, one major limitation of
this technology is the failure to detect post-translational
modifications.
PROTEOMEX/SERPA
In addition to SEREX, PROTEOMEX also termed SERPA
was developed using two-dimensional polyacrylamide
gel electrophoresis (2D-PAGE) followed by Western blot
analysis of the gels followed by their incubation with
sera of patients and healthy volunteers [143, 144]. In
addition, two-dimensional immune affinity chromatog-
raphy followed by proteolysis and mass spectrometry
has been used to identify novel TAA or respective bio-
markers. Although these tools are very robust, the disad-
vantages of these proteome-based technologies are their
labor intensity with limitations in sample capacity, while
the mapping could be automated in the future.
Protein arrays
Other proteome-based high-throughput analyses include
automated protein microarrays of serum antibodies from
cancer patients versus healthy controls. With this tech-
nology, a large series of proteins can be evaluated, which
are either derived from cDNA or peptide phage display
libraries [145]. By using protein arrays with a known
panel of proteins, an induction of antibody responses
against TAA has been recently demonstrated in a study
using ipilimumab associated with GM-CSF treatment
[146]. The development of antibodies to NY-ESO-1 post-
treatment was identified in one clinical responder and one
non-responder, suggesting that immunotherapy can in-
duce immune responses to other known TAA. Other
sources for immune genomic arrays apart from libraries
include recombinant proteins or tumor lysates. The
implementations of recombinant proteins for the array are
multiple, but also more costly and may not account for
post-translational modifications like SEREX. In order to
take into account the effects of post-translational modifi-
cations on epitope recognition with respect to aberrant
glycosylation of the tumor protein, high-throughput ana-
lysis using a glycopeptide discovery platform for proteo-
mics profiling has been developed [147]. Although this
glycopeptide platform allows high-throughput analyses, it
has yet to be validated in particular regarding reproduci-
bility and stability of this technique.
SomaScan
Aptamer-based protein array monitoring has recently
become available. A particular form of modified aptamers
with slow off-rate (SOMAmers) allows for the compara-
tive evaluation of proteins in as low as 70 μl of serum or
plasma (or other biological fluids). The SOMAscan assay
is highly multiplexed, sensitive and quantitative. This assay
is based on the use of a new generation of protein-capture
SOMAmer reagent [148]. Native proteins contained in
biological samples are captured by SOMAmers immobi-
lized on streptavidin-agarose beads via a photo-cleavable
biotin linker. Unbound proteins are washed away. The
proteins captured are then biotinylated, the complex bio-
tinylated protein/SOMAmer is released from the capture
beads by the UV-induced photocleavage of the photo-
sensitive linker. Magnetic-streptavidin beads capture the
freed protein-SOMAmer complexes while the SOMAmers
that did not bind to a protein are washed away. Captured
SOMAmer-protein complexes are then denatured and the
SOMAmers (each containing a unique 40-nucleotide tag)
are hybridized onto a high-density array of complemen-
tary probes. The hybridized SOMAmers are detected on a
DNA array reader, which quantifies the presence of
each SOMAmer using classic DNA detection methods.
By transforming each individual protein concentration
into a corresponding SOMAmer reagent concentration,
the SOMAscan assay is not limited by variation be-
tween lots of protein standards. The SOMAscan assay
measures over 1300 protein analytes that cover a di-
verse set of molecular functions. Targets to date exten-
sively cover major gene families including receptors,
kinases, growth factors, and hormones, and span a di-
verse collection of secreted proteins, including cyto-
kines and their soluble receptors, and intracellular and
extracellular proteins or domains. The assay covers a
wide concentration range by using a systematic dilution
scheme based on the normal abundance of the protein
measured. The analysis of the SOMAscan is performed
using classic DNA array data analysis and is based on
bioinformatics tools that have been developed for gene
array analysis.
Multiplexed ELISA-type assays
Chemokines and cytokines are small molecules, which
play an important role in an array of physiologic, but
also pathophysiologic acute (e.g. infections) and chronic
(e.g. cancer) immune responses. Therefore the measure-
ment of chemokines and cytokines can be used to moni-
tor the immune system, as the composition of these
small molecules yields insights into the immune cell rep-
ertoire and functions both in the disease state as well as
in response to immunotherapy [149]. In addition, soluble
adhesion molecules and MMP are also suitable bio-
markers for clinical trials [22].
Historically, the assessment of cytokines and chemo-
kines has been performed with the single-plex ELISA.
Despite the accuracy and value of this technology, it has
a limited scope, since determination of the cytokine net-
work interaction is precluded. Furthermore, this method
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is costly, time consuming, requires a relatively large sam-
ple size, and can only measure one analyte per sample.
Multiplex immunoassays measuring multiple biomarkers
have since been developed and represent an important
tool to monitor immune responses [150]. Using the lumi-
nex technology, it is possible to evaluate >100 cytokines/
chemokines simultaneously with a minimal amount (ap-
proximately 50 μl) of sample thus avoiding sample pooling
[151, 152]. For the implementation of this assay in clinical
trials it is important to determine the accuracy and reli-
ability (including potential antibody cross-reactivity) of
the detection method for each analyte. Furthermore pre-
analytical variables, such as the anti-coagulant used for
the collection of blood, sample preparation, time and
temperature storage of samples as well as gender and age
of the donor also have an impact on the cytokine/chemo-
kine measurement using luminex and ELISA [152–154].
However, no single method of specimen preparation was
clearly superior for the measurement of cytokines. Al-
though there exist anti-coagulant-dependent differences
in analyte concentrations, the relative concentrations of
the various analytes remain similar for a given anti-
coagulant [154].
Transcriptomics
Gene expression profiles reflect the systemic immune
milieu and can be used for immune monitoring pur-
poses as well as to identify predictive biomarkers. In
melanoma patients treated with tremelimumab, an IgG2
antibody that targets CTLA-4 on T cells, a genomic sig-
nature predictive of prolonged survival has been recently
identified, consisting of four gene transcripts [155]. Pre-
treatment gene expression signatures have also been
identified in patients with melanoma and NSCLC receiv-
ing MAGE-A3 immunotherapy. Eighty-four genes were
identified, in which expression correlated with better
clinical outcome [156]. The genes identified were mainly
immune-related, including IFN-α and γ pathways and
specific chemokines, highlighting the concept that pre-
treatment gene expression patterns can influence the
TME and the patient’s clinical response. The transcrip-
tional profiles of sentinel node biopsies from melanoma
patients suggest that infiltration with CD30+ lympho-
cytes positively associates with disease progression [157].
Microarrays have been very useful for the high-
throughput analysis of gene and miRNA expression,
but they are limited by the requirement for the use of
relatively large quantities of high quality RNA. Next-
generation sequencing (NGS) can be used for high-
throughput gene expression analysis, but this technology
remains costly and data analysis is difficult. Microarrays
and NGS have been important discovery tools since
they measure the entire transcriptome; however, their
use for most immunotherapies is generally restricted
to assessing the expression of sets of genes targeted
to cells, tumors or pathways of interest, thus repre-
senting an opportunity to further take advantage of
these powerful tools in the discovery and assessment
of biomarkers [158].
Quantitative PCR (qPCR) provides a more accurate
measurement of gene expression than microarrays and
requires less RNA, but the analysis of the expression of
multiple genes with classical qPCR is difficult. Nanoflui-
dics has been used with PCR to make multiplex PCR
less labor intensive and less costly. Nanofluidic instru-
ments are available which allow for high-throughput
multiplex PCR analysis. One instrument, the BioMark™
system (Fluidigm Corporation) allows for the simultan-
eous performance of 48 or 96 PCR assays on 48 or 96
samples [159]. This platform can be employed for the
analysis of both gene and miRNA expression and has
been implemented to measure the expression of more
than 90 genes or miRNAs [160, 161]. Digital PCR can
also be used for high-throughput high-precision analysis,
but multiplex PCR is more difficult. Digital PCR can be
performed on chips or in droplets [162, 163].
Molecular “bar coding” is being used for the high-
throughput analysis of the expression of multiple genes.
The nCounter Analysis System (NanoString Technolo-
gies, Inc.) can measure RNA levels of more than 700
genes. Requiring no amplification step, it directly mea-
sures low quantities of mRNA using molecular bar codes
and digital molecular imaging [79].
Genome mutation analysis
Somatic mutation can play a critical role in cancer de-
velopment and progression. Tumor genotyping is im-
portant for classifying tumors and predicting response
to directed therapies. SNP and other mutations can be
detected by fluorescence in situ hybridization (FISH),
PCR with sequence-specific primers or probes and
Sanger sequencing. These methods are limited by the
need for relatively large quantities of DNA and they are
relatively slow and expensive, especially when analyzing
for multiple mutations [164].
Whole genome or exon sequencing using NGS plat-
forms can be used to analyze the entire genome, but
this is not yet practical for routine clinical analysis be-
cause of the high cost and large amount of data analysis
required. Targeted NGS reduces data analysis require-
ments and is used for the targeted analysis of mutations
in cancer genes. The targeted sequences can be isolated
using sequence-specific primers or probes and multiple
loci can be targeted [165]. Nanofluidic platforms and
PCR have also been used with NGS to analyze multiple
loci [166]. Customized microarrays can also be used for
targeted SNP analysis (GeneChip Custom SNP Kits,
Affymetrix).
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Analysis of the systemic host response
The systemic assessment of immune regulation and
modulation can quickly result in a morass of data that
spans patients, time points, assays, tissues, and organiza-
tions. For example, tissues sampled from a given patient
might include PBMC, serum, tumor biopsies, and TDLN
and these might be assayed by a combination of flow or
CyTOF (cytometry by time-of-flight) phenotyping,
phospho-flow, Luminex or protein arrays, and gene ex-
pression. Organizational considerations might include
multiple cores at the same or different institutions, and
academic, government, and industry participants from
multiple countries. Consequently, the analysis of such
multifaceted data may be fragmented by assay or
organization in ways that undermine measurement of
the systemic response. To increase the value of these ex-
pensive and complex data sets, the data must be merged
into a consistent assay-agnostic format that spans assays,
tissues, and organizations. This integrated heterogeneous
data set can be referred to as a “het set.”
The het set offers several advantages, the first of which
is that it supports the goals of capturing and characteriz-
ing the systemic host response. A het set also provides a
common technical and conceptual representation of an
otherwise unwieldy data set and the same analytical tools
and techniques can be applied to hundreds or thousands
of analytes from multiple assays. Finally, established multi-
variable analytical approaches can be applied to the inte-
grated whole, with an emphasis on results that span assays
or tissues. Table 1 provides a small extract from a repre-
sentative het set in a “long” format, with a single data
point occupying each row. It should also be noted that
data from different assays might require processing or
normalization prior to inclusion in the het set [57].
Once a het set has been created, a variety of well-
established analytical principles and techniques can be
considered [167]; novel analytical approaches are not
necessarily needed to obtain novel scientific findings or
to improve patient care. A common example of an ana-
lytical goal that can be supported by a het set is the
identification of biomarkers that distinguish responders
from non-responders. This is considered a classification
problem, which is fundamentally different than looking
for analytes that are statistically different between
responders and non-responders. This scenario calls for
a “supervised” algorithm, in which we know the answer
(response, non-response) and are looking for a set of
analytes that help us arrive at that answer. A decision
tree is one such supervised approach. Alternatively, if
one is looking for a variety of patterns in the data that
help us to better understand the relationships between
patient characteristics and analytes, then an “unsuper-
vised” approach, in which there is not a specific answer
is appropriate. Hierarchical clustering and association
rule mining are examples of unsupervised approaches.
Ideally, the analytical approaches will provide both
quantitative and visual results. Another consideration is
whether the analytical techniques are magnitude-
insensitive, that is, able to easily support data from
assays yielding wildly different numeric ranges. Further-
more, the results suggested by any analysis should be
vetted for biological relevance and replicated in inde-
pendent data sets or studies. The following five tech-
niques, detailed below, can provide insight into the
systemic host response and are applicable to het sets:
regression modeling, network of cross-compartment
correlations, penalized regression, decision tress, and
association rule mining.
Regression modeling supports both simple models
(such as response α β1 x analyte) and more complex
models (such as response α β1 x analyte + β2 x treatment
+ β3 x sex + β4 x age). In both simple and complex
models, the β terms are the estimated coefficients or
contributions of the predictor variables to the outcome
variable. Complex multivariable models can be longitu-
dinal models or time-to-event (survival) models and ac-
count for variables like treatment type, sex, and age.
Longitudinal models may be particularly appropriate for
characterizing immune response over time and can ac-
count for patient-specific trends. Response can be categor-
ical (responder versus non-responder) or continuous
(progression-free survival). A strategy that is common in
gene expression analysis is to build such a model for all
genes and focus on a handful with the smallest p-values
on the coefficient of interest. While it is fast and easily
understood, this approach does not provide a comprehen-
sive picture that accounts for systemic responses or for
correlations amongst analytes.
Table 1 Sample extract from a representative integrated heterogeneous data set (het set)
Person Day Tissue Assay Analyte Readout Units
1–52 0 PBMC Flow phenotyping CD4+ Treg 3.2 % of parent
1–52 0 Tumor Flow phenotyping CD4+ Treg 5.1 % of parent
1–52 0 Serum Luminex IL2 3.8 pg/ml
1–52 1 Serum Luminex IL2 2.7 pg/ml
1–52 5 Serum Luminex IL2 2.5 pg/ml
1–52 0 Whole blood RNA Gene expression IL2 10.1 log normalized expression
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One approach to building a systemic network of cross-
compartment correlations is to start with a regression
model in which one analyte is the outcome and another
is the predictor, e.g., assayA.analyte1 ~ β1 x assayB.ana-
lyte2 + β2 x response. As with multivariable regression, a
variety of other predictors can be included in the model.
Once the model results for all possible pairs of analytes
are obtained, the results can be filtered to pairs of ana-
lytes from different assays or tissues and have reasonably
small p-values on effects of interest, such as both the
correlation between the analytes, and the effect of the
response. Given 50 to 100 of such correlations, the rela-
tionships across the analytes can be tallied and the net-
works of correlations can be visualized. For example,
Whiting et al. identified a network of 61 highly corre-
lated analytes spanning flow phenotyping, phospho-flow,
and serum proteins as measured by Luminex, after ac-
counting for age, sex, and cytomegalovirus status. Of
these, 9 analytes were connected to at least 7 other ana-
lytes [168]. This approach provides the flexibility of a
regression-modeling framework, while accounting for all
possible pairwise correlations between analytes and fil-
ters allow for cross-assay or cross-tissue correlations.
Additional approaches to network analysis are reviewed
by Wang and Huang [169].
A penalized regression approach, such as lasso or
elastic-net [170, 171], selects a subset of variables that
best predict outcome, in part by constraining a function
of the sum of the regression coefficients, and the out-
come can be categorical or numerical. Penalized regres-
sion has been used by researchers to predict SLN11
levels in breast cancer patients [172], to predict post-
treatment levels of CD137+ NK cells in various cancers
[173], and to model progression-free survival as a func-
tion of serum cytokines [174]. One advantage of this re-
gression approach is that it performs both feature
selection and model building in a single pass. A limita-
tion of this approach is that all analytes are normalized
prior to model building, and numeric results are
expressed in terms of standard deviations from the mean
of any particular analyte. This can complicate both inter-
pretation and application to subsequent data sets. Essen-
tially, we have to assume that the mean and standard
deviation of any particular analyte in our working data
set are comparable to that in a replication set.
Decision trees are a supervised machine learning tech-
nique for classification. The algorithm interrogates all
analytes to find the one that best splits the observations
into categorical outcomes such as responder and non-
responder. Then, it interrogates all remaining analytes to
find the next best split, and so on, until a series of splits
yields relatively pure groups. Advantages of decision
trees include ease of interpretation, support for both
continuous and categorical attributes, and support for
analytes of a variety of scales. Furthermore, they can be
particularly useful when data is bimodal—for example,
very high Treg and very low Treg. O’Donoghue et al.
used a decision tree on gene expression to classify good
and poor prognosis in dogs diagnosed with canine osteo-
sarcoma [175]. Random forests are an extension of deci-
sion trees, in which hundreds or thousands of trees are
built from randomly selected subsets of both analytes
and patients. Patients are then classified based on their
most common assignment across all of the trees. Re-
searchers have used this approach to identify serum
proteins that can stage prostate cancer patients [176].
Random forests have the advantage of being more ro-
bust to data outliers. The method has also been ex-
tended to support time-to-event (survival) data [177].
However, the resulting model is not easily visualized
since it includes many trees.
Association rule mining is an unsupervised machine
learning technique for pattern identification. Since it
works only on categorical data, continuous data must be
first converted to categorical data. Such conversions can
be quantile-based (e.g. quartile) or based on reference
ranges (below, within, above) [178]. Association rules
yield “if-then” statements such as “If Ki67 expression is
low and IHC score = 2, then the HER2:CEP17 ratio (as
measured by HER2 FISH pharmDx) is negative (less than
2:2),” reported in a study of breast cancer patients [179].
Association rules can be quantified by the percentage of
the study population to which they apply, and the percent-
age of the time that they are true. As with the pairwise re-
gression models discussed above, association rules can be
filtered for those that span assays or tissues.
These are only a few of the many approaches available
for analyzing multivariable multi-assay data sets. Others
include principle component analysis, hierarchical clus-
tering, and artificial neural networks. Given a het set
that includes data from multiple assays, time points and
tissues, the systemic host response can indeed be ana-
lyzed in an assay-agnostic manner.
Clinical application of immune monitoring
Approach to monitoring immunotherapy for GI
malignancies
Immune-based treatment approaches have revolutionized
oncology in recent years. Various treatment strategies
have received US Food and Drug Administration (FDA)
approval including cell vaccination for prostate cancer as
well as immune checkpoint inhibition targeting the
CTLA-4 or the PD-1/PD-L1 axis in melanoma, lung, and
kidney cancer. Additionally, cell based therapies (adoptive
T cell therapy, chimeric antigen receptor [CAR] T cells
and, TCR transduced T cells) have demonstrated substan-
tial efficacy in patients with B cell malignancies and mel-
anoma. Immune checkpoint inhibitors in particular have
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generated enormous excitement across the entire field of
oncology, providing a significant benefit to a minority of
patients as well as teaching us a great deal about the im-
mune system in our efforts to predict who will benefit
from treatment. However, with some notable exceptions,
most studies in patients with tumors of the GI tract using
this type of treatment approach have been disappointing.
One of the first studies demonstrating impressive results
of PD-1/PD-L1-directed therapy was discouraging from a
GI cancer viewpoint [180]. There were no responses in
any of cohorts containing patients with colorectal (N = 18),
pancreatic (N = 14), and gastric (N = 7) cancer. Similarly,
negative results for GI cancers were seen in other studies
of both anti-PD-1 and anti-CTLA-4 therapy [181–183].
Mismatch repair deficiency and anti-tumor immunity
One notable exception to this disappointing preliminary
experience has been in mismatch repair-deficient CRC
where significant responses to PD-1 pathway inhibition
have been observed [184]. The defective mismatch
repair system results in a marked increase in the non-
synonymous mutagenic burden within tumors, increas-
ing the likelihood that a tumor-specific neoantigen,
capable of recognition by the immune system, is gener-
ated [185]. This is certainly relevant for any tumor type
that happens to have a high mutagenic burden because
of either inherited or acquired mismatch repair defi-
ciency – resulting in a degree of microsatellite instability
(MSI) – or other factors. Various tumors of the GI tract
have been shown to occur in patients with inherited mis-
match repair deficiency. MSI is present in 10–20% of
sporadic colorectal [186], gastric [186], and ampullary
cancers [187]. Between 0.3 and 13% of pancreatic can-
cers are reported to have MSI as well [188] and recently
a small proportion (5.9%) of biliary cancer have been
identified to have a high mutational load [189]. Conse-
quently, immune monitoring has become important for
GI malignancies (Table 2).
Anti-viral responses as surrogate markers for an active
immunotherapy
A number of GI cancer types are typical inflammation
associated tumors. Almost 90% of all patients with hepa-
tocellular carcinoma (HCC) also show an underlying
liver disease. Chronic viral hepatitis (hepatitis B virus
[HBV] and hepatitis C virus [HCV]) is a major risk
factor for the development of liver cirrhosis and HCC.
Immune checkpoint inhibitors are currently being eval-
uated in HCC patients with underlying chronic HBV
and HCV infection. Interestingly, not only did tremeli-
mumab show early signs of anti-tumor efficacy, but it
also induced a decrease in HCV viral load from 3.78 x
105 IU/ml at day 0 to 1.69 x 103 IU/ml. In parallel, the
investigators observed a general trend to increased
number of virus-specific IFN-γ-producing lymphocytes
post-treatment [38]. We have observed similar effects
in HCC patients with chronic HBV or HCV infection
[190]. In summary, anti-viral responses can be used to
track the effect of those approaches aiming to enhance
antigen-specific T cell immunity.
Liver toxicity
Immune-stimulatory mAbs are currently being evaluated
as antitumor agents. Although overall toxicity from
immunotherapy drugs such as anti-CTLA-4, anti-PD-
L1/PD-1, and anti-CD40 appears to be moderate, liver
toxicities have been reported and are not completely
understood.
Transient dose-related elevations in serum liver trans-
aminases and total bilirubin were observed after infusion
of anti-CD40 [191]. It was thought that this effect was
due to CD40+ hepatocytes, which underwent apoptosis
upon CD40 activation. We have been able to show that
agonistic CD40 antibody caused liver damage within
24 h after injection in a variety of different murine
tumor models. Here, liver damage was induced by the
generation of reactive oxygen species produced by intra-
hepatic myeloid cells, which accumulate in the liver of
tumor-bearing individuals [192]. Therefore, liver toxicity
may be mediated by anti-CD40 activated intrahepatic
myeloid cells rather than a direct effect of anti-CD40 on
hepatocytes [193]. Transient transaminitis has also been
observed in patients with HCC treated with tremelimu-
mab [38]. A remarkable rise in serum transaminases was
observed after the first dose in more than half of the pa-
tients. However, it was not associated with a parallel de-
cline in liver function and did not recur in the following
treatment cycles.
This observation was unexpected since inflammatory
hepatic adverse events (AE) related to anti-CTLA-4 were
Table 2 Monitoring immunotherapy for GI malignancies
Marker Specimen Use
MSI Tumor Determine eligibility for anti-PD1 treatment
Quant HCV Serum Response to anti-CTLA-4 treatment in patients with HCV infection
Pathology Liver biopsy Rule out drug induced hepatitis
ALT/AST Serum Liver toxicity
Gut microbiome Stool Response to treatment with immune checkpoint inhibitors
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uncommon in clinical studies. Of any grade, these AE
were reported in 3.8% (5/131) of patients treated with
ipilimumab monotherapy at 3 mg/kg in a phase III trial
[194]. Kleiner and Berman studied 5 patients in which a
liver biopsy was taken to rule out drug-induced auto-
immune hepatitis.
The histologic changes observed with ipilimumab-
related hepatitis were similar to those with acute viral
and autoimmune hepatitis and it was not possible to
make a definite diagnosis of a drug-induced hepatitis.
Hepatic inflammation in the five patients reported re-
solved with appropriate immuno-suppressive therapy,
and the authors suggest that patients who receive im-
mune checkpoint inhibitor therapy should be monitored
at regular intervals for biochemical and pathological evi-
dence of hepatitis so that appropriate treatment can be
promptly administered [195].
Endoscopy
Patients undergoing immune checkpoint therapy could
develop enterocolitis as an adverse event [195]. A com-
mon side effect in such instances is diarrhea, which war-
rants endoscopic procedures such as upper endoscopy
and colonoscopy. It should be noted that these tests can
also be used to obtain tumor biopsies and monitor pro-
gress during the course of treatment.
Biomarkers and cell therapies
Characteristics of adoptively transferred cells associated
with better clinical outcomes
The adoptive transfer of TIL for the treatment of patients
with metastatic melanoma has produced promising
clinical results. More favorable clinical results have
been associated with greater in vivo persistence of in-
fused TIL one month after therapy [196]. Characteris-
tics of TIL that correlate with more favorable outcomes
include longer telomeres and the administration of lar-
ger numbers of TIL, CD8+ cells, and CD8+CD27+ T
cells [196, 197]. TIL that spend less time in culture, so-
called “young” TIL, have a phenotype consistent with
an earlier differentiation state including longer telo-
meres and higher levels of CD27 and CD28 expression
[198–200] and these cells may be more effective clinic-
ally [197]. Analysis of TIL cells obtained from patients
with metastatic melanoma has shown that reduced ex-
pression of the chemokine receptors CXCR3 and CCR5
and the presence of the CCR5-Δ32 polymorphisms,
which encodes a protein that is not expressed, were as-
sociated with better response to TIL therapy [201].
Preclinical models have shown that the phenotype of
adoptively transferred T cells can influence their effect-
iveness. Antigen-specific central memory T (TCM) cells
are more effective for adoptive T cell therapy than ef-
fector memory T cells; transferred TCM survive longer in
vivo [202]. Adoptively transferred memory T cells that
have stem cell-like qualities, stem memory T cells
(TSCM), result in greater in vivo expansion, longer per-
sistence and better anti-tumor activity [203, 204]. TSCM
are characterized as CD45RA+, CD62L+, CCR7+, and
CD95+. Some investigators are developing methods to
enrich adoptively transferred T cells with TSCM or TCM
characteristics [205].
Clinical studies of adoptively transferred T cells engi-
neered to express CAR have found that the in vivo ex-
pansion of these cells also been associated with favorable
clinical outcomes [206]. When CD19 CAR T cells are
used to treat children and young adults with acute
lymphoblastic leukemia, the transferred T cells can ex-
pand several-fold. Peak expansion of CD19 CAR T cells
occurred at 14 days post-infusion and the cells persisted
up to two years [206, 207]. Peak expansion was associ-
ated with disappearance of circulating leukemic blasts in
responding patients. Patients responding to the therapy
had higher levels of circulating CD19 CAR T cells than
those that did not respond [206].
Tumor-trafficking potential of adoptively infused T cells
The trafficking of effector T cells to tumor sites is a pre-
requisite for their antitumor activity. Tumor irradiation
has been shown to shape a pro-inflammatory micro-
environment that permits the extravasation of T cells
and promotes their effector function [208].
CD19-targeted T cells may be more rapidly cleared
from the circulation in the presence of a higher periph-
eral blood tumor burden, likely as a result of tumor infil-
tration and disappearance from the circulation [209].
However, in a patient with chronic lymphocytic leukemia
who died 44 h after CAR T cell infusion, staining of aut-
opsy tissues with anti-CAR antibodies showed rapid T
cell trafficking to tumor sites, including lymph nodes,
bone marrow, and liver [209]. Studies of autologous
anti-LeY CAR immunotherapy in patients with acute
myeloid leukemia have shown migration of the adop-
tively infused T cells to the bone marrow and the skin,
as well as persistence for up to 10 months [210].
CAR T cells containing the CD28 endodomain may be
endowed with enhanced expansion potential and persist-
ence compared with CAR T cells lacking this endodo-
main [211]. The analysis of skin biopsies from a patient
with non-Hodgkin lymphoma showed that 20% of the
gated CD3+ lymphocytes co-expressed the CAR. This
study clearly demonstrates that one of the incremental
benefits of incorporating critical costimulatory compo-
nents into CARs is the ability of T cells to infiltrate and
mediate anti-tumor effects in tissues.
The tumor trafficking potential of activated T cells
bearing a CAR specific for the tumor antigen GD2 can
be enhanced by forced co-expression of the chemokine
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receptor CCR2b, which directs migration towards CCL2,
a chemokine produced by several tumors. This strat-
egy translated into improved homing (>10 fold) to
CCL2-secreting neuroblastoma compared to CCR2-
negative T cells, as well as greater in vivo anti-tumor
activity [212]. Forced expression of CCR4 by effector
T cells has been shown to enhance their migration to
the Reed-Sternberg cells of Hodgkin lymphoma (HL)
[213], which predominantly produce TARC/CCL17
and MDC/CCL22. Furthermore, T cells expressing
both CCR4 and the HL-associated antigen CD30 man-
ifested greater cytotoxic function and in vitro cytokine
secretion, and mediated better tumor control in mice
engrafted with human HL [213].
Monitoring the levels of adoptively transferred T cells
Monitoring the circulating levels of adoptively trans-
ferred TIL and lymphocytes engineered to express CAR
or high affinity TCR is important for improving the ef-
fectiveness of these therapies. The survival of T cells
can be monitored by labeling a fraction of the cells with
radionuclides such as chromium-51 or indium-111,
however radiolabeling requires dedicated space, highly
trained staff, and it is not widely available. The intravas-
cular persistence of T cell clones prepared from TIL
can be measured by TCR-specific PCR [214]. T cell
clone persistence can be monitored by amplification of
the TCR beta-chain region gene and the relative expres-
sion of the TCRBV gene products can be determined
using a panel of monoclonal antibodies and flow cy-
tometry [215]. This method has been used to show that
the degree of persistence in the peripheral blood of
adoptively transferred T cell clones was associated with
melanoma regression [215]. Another study found that
the persistence for one month of adoptively transferred
T cell clones prepared from TIL was associated with
clinical responses [196]. While this technique has pro-
vided important insights, it is limited by the need to
isolate and characterize clones. In addition, the quanti-
tative ability of this assay is limited.
Monitoring the levels of CAR T cells in the peripheral
blood is easier and has yielded important information.
The percent of T cells expressing CARs can be measured
using flow cytometry. If the scFV region of the monoclo-
nal antibody used in the CAR is of mouse origin, then
goat antibodies directed to mouse F(ab)2 can be used to
quantitate CAR T cells. To detect CD19 CAR T cells by
flow cytometry, anti-Fab antibody staining and labeled
CD19 protein have been used [216]. Flow cytometry
using anti-idiotype monoclonal antibody has been used
to detect CD19 CAR T cells derived from CD19 mouse
monoclonal antibody clone FMC63, [206, 217, 218].
CAR T cell expansion can also be detected by quantita-
tive qPCR [219, 220].
Cytokine release following cell infusion
The rapid expansion of adoptively transferred CD19
CAR T cells and the disappearance of leukemic cells is
associated with clinical toxicity due to cytokine storm
[221]. Cytokine release syndrome (CRS) is a non-antigen
specific toxicity that occurs as a result of high levels of
activation of lymphocytes or myeloid cells. It is associated
with elevated circulating levels of several cytokines includ-
ing IL-6, IFN-γ, and TNF-α. Clinically, patients with CRS
may experience fever, tachycardia, and hypotension. It can
result in cardiac dysfunction, adult respiratory distress
syndrome, renal failure, hepatic failure, or neurotoxicity
[221]. It is more likely to occur in patients with higher
tumor burdens and greater T cell expansion [207, 221].
IL-6 appears to play an important role in the pathogenesis
of CRS and the anti-IL-6 receptor antibody, tocilizumab,
is often an effective therapy. The clinical use of toci-
lizumab has also been explored in patients with acute
lymphoblastic leukemia who develop CRS after blinatu-
momab immunotherapy [222].
CRP has been found to be an effective biomarker for
CRS [221]. CRP is an acute phase reactant produced by
the liver. Its production is largely dependent on IL-6. In
patients with ALL treated with CAR T cells, CRP levels
have been found to be associated with the IL-6 levels
and CRS severity [206].
Conclusions and recommendations
The field of immune monitoring has helped advance im-
munotherapy for cancer. All clinical trials of immune
therapies for cancer should include a structured plan for
sample collection, biomarker analysis, and data analysis.
Sample collection and analysis must be adopted for each
study, but several points should be considered (Table 3).
Table 3 Type of sample and high throughput assessments






PBMC • Flow cytometry
• Phospho-flow cytometry
• MHC multiplexed multimers
• nCounter Analysis System (NanoString)
• qPCR
• Gene expression microarrays
• NGS
• miRNA expression analysis
• ImmunoSEQ
Tissue • Multiplexed IHC or immunofluorescence
• Flow cytometry
• qPCR
• Gene expression microarrays
• NGS
• miRNA expression analysis
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 Due to the complexity and our current limited
understanding of the underlying biology of cancer
immunotherapies, routine, direct evaluation of
tumor samples, archival as well as fresh paired
tumor samples and direct comparison to peripheral
samples, should be considered as a high priority.
 In addition to analyzing plasma, serum, and peripheral
blood leukocytes, consideration should be given to the
analysis of tissue samples, the microbiome and, if
appropriate, adoptively transferred immune cells.
 Mutiplexed, high throughput assessment allows for
the analysis of multi-analyte signatures which can
lead to a better understating of key mechanisms and
the identification of biomarkers.
 Analysis might include flow cytometry, high
throughput proteomics, mRNA, miRNA, and
DNA mutagenous assays (Table 3).
 Computation biologists should be enlisted to best
assess the systemic immune response for expertise
in combining data across platforms correctly
(Table 1).
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